DOCSLIB.ORG

GSPH Formatted CV Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GSPH Formatted CV Template CURRICULUM VITAE Biographical Information NAME: Radosveta Koldamova, MD, PhD CITIZENSHIP: United States of America BUSINESS ADDRESS: Department of Environmental and Occupational Health, Graduate School of Public Health, 100 Technology Drive, BRIDG Building, Room 551 Tel, Office: 412 383 7197 Tel, Lab: 412 624 8662 Fax: 412 383 7658 Email: [email protected] EDUCATION AND TRAINING Undergraduate Years of NA NA NA Attendance Graduate 1973 – 1979 Medical Academy, MD, General Medicine Sofia, BULGARIA 1979 1989 - 1994 Medical Academy & PhD, Molecular Biology Bulgarian Academy of 1994 and Biochemistry Sciences, Sofia, BULGARIA Post-Graduate 1995-1998 Department of Postdoctoral fellow Pharmacology Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA 1 1 APPOINTMENTS AND POSITIONS Academic 2011-present Res. Associate professor Department of Environmental and Occupational Health, University of Pittsburgh. October 1, 2005 – Res. Assistant Professor Department of Environmental and 2011 Occupational Health, University of Pittsburgh. Feb 1, 2005 – Sept Res. Assistant Professor Department of Pharmacology, University of 31, 2005 Pittsburgh 1998 – January 31, Instructor Department of Pharmacology, University of 2005 Pittsburgh, Pittsburgh, PA 1991-Oct 30, 1995 Assistant professor Department of Biochemistry, School of Medicine, Stara Zagora, BULGARIA 1986-1990 Instructor Department of Biochemistry, School of Medicine, Stara Zagora, BULGARIA 1983 - 1985 Lecturer Department of Biochemistry, School of Medicine, Stara Zagora, BULGARIA Non-Academic 1980 – July 30, General Practitioner Regional Hospital Strazhitza, BULGARIA 1982 CERTIFICATION AND LICENSURE Specialty Certification 1986 Board certified in Medical Medical Academy, Sofia, Biochemistry BULGARIA. Medical or Other Professional Licensure NA NA NA 2 2 MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES 2008 – Present time International Society to Advance Alzheimer Research and Treatment 2004 – Present time Society for Neuroscience 2003 – Present time American Society for Biochemistry and Molecular Biology 1996-1998 American Association for Cancer Research HONORS 1997 AACR - Pharmacia & Upjohn Young investigator Award 1998 AACR - Pharmingen Young investigator Award PROFESSIONAL ACTIVITIES: Teaching Courses Taught 2013 – Graduate School of Hours of Human genetics 2034 present Public Health, Lecture – 5 Biochemical and time University of classes (2 Molecular genetics of complex disease Pittsburgh hours each); 28 students (Epigenetic mechanisms in human pathology) School of Medicine, Stara Zagora, Bulgaria 1983-1995; Title: Biochemistry, Hours of Role in course: School of Metabolism, Lecture – 9 Primary instructor Medicine, St. Molecular Biology hours Zagora, BG Second year medical students weekly; 2 semesters; 75 students Other Teaching (lectures, tutorials and continuing education courses) Date(s) Type of Teaching Title March-April, 2014 Guest mentor for Medical Scientist "Research Basis of Training Program Medical October 12, 2011 Guest mentor for Medical Scientist Knowledge." Training Program "Research Basis of Medical Knowledge." 3 3 Graduate Student Essays, Theses, and Dissertations Name of Degree Type of Document and Title Notes Student Awarded, Year Alexis Y. Second year Carter PhD student Service on Masters or Doctoral Committees Dates Name of Degree Title of Dissertation/Essay Served Student Awarded January 2012- Xiaozhuo Lu MS THE ROLE OF ATP-BINDING CASSETTE April 2012 TRANSPORTER A1 ON AMYLOID Mark Wong PATHOLOGY IN APP MICE EXPRESSING 2013 Chen DIFFERENT APOE ISOFORMS ENVIRONMENTAL EXPOSURE TO ARSENIC AND ITS RELATION TO GENOME-WIDE MODIFICATION IN GESTATION MOUSE OFFSPRING Service on Comprehensive or Qualifying Examination Committees: NA Supervision of Post-Doctoral Students, Residents, and Fellows Dates Supervised Name of Student Position of Student 2007 – 2013 Nicholas Fitz, PhD Postdoctoral fellow 2007 – 2013 Andrea Cronican, PhD Postdoctoral fellow 2012-present Alexis Carter Graduate student March 2014-present Kyong Nam PhD Postdoctoral fellow April 2014-present Danko Georgiev MD, PhD Postdoctoral fellow April 2014-present Anais Mounier PhD Postdoctoral fellow 2014-present Emilie Castranio Graduate student 2014-present Cody Wolfe Master student 2012-2013 Mark Wong Chen Master student 2012-2013 Xiaozhuo Lu Master student 4 4 Mentoring of Graduate Students in Field Placements-NA Other Teaching and Training: University of Pittsburgh Undergraduate Training Dates Teaching Activity Program/Description May 2011 – Muzamil Saleem, MS Predoctoral Student August 2013 Undergraduate, Department of Aug-212-present Iana Vodianova Neuroscience Aug-212- Undergraduate, Department of Luv Purohit December 2013 Neuroscience Simrath Randhawa, Aug-212-April Undergraduate, Department of 2013 Neuroscience Alexis Carter Aug-212-April EOH Summer Undergraduate Research 2013 Program Sai Pratyusha Kancherla June –Aug 2011 ndependent research study Priya Rajendran “Identifying Novel LXR May –Aug 2011 EOH Summer Undergraduate Research Activators for a Potential Program June -Aug 2009 Therapy for AD” June -Aug 2009 Sean Egglestone EOH Summer Undergraduate Research “The Role of ABCA1 in Program Aβ Aggregation and Spatial Memory Formation in the APP Mouse Model” June -Aug 2008 Mitchell Thompson III EOH Summer Undergraduate Research “Role of Abca1 in Program Learning and Memory of Alzheimer’s Disease Mouse Model” June -Aug 2008 Alexis Carter Pitt STEER Program for High School “Importance of Cholesterol Students Metabolism in the Pathology of Alzheimer’s Disease” 5 5 RESEARCH AND TRAINING Grants and Contracts Received Years Grant and/or Contract Source Annual Effort Inclusive Number and Title Direct Costs 05-2013-04- 1R01AG037481-01A1 LXR NIA-MINORITY 2016 and Human ApoE Isoform SUPPLEMENT Effects on AD Phenotype: in 04/01/2011 vitro and in vivo models NIH/NIA $250,000 40% 03/31/2016 1R01AG037481-01A1 LXR and Human ApoE Isoform Effects on AD Phenotype: in vitro and in vivo models PI 02/01/2007 R01AG027973-01A1 Role of NIH/NIA $225,000 50% 01/31/2012 ABCA1 in neurodegeneration PI 10/02/2009 R01AG027973-04S1 Role of NIH/NIA $30,000 0 05/26/2010 ABCA1 in neurodegeneration- Administrative Supplement PI 2005-present Role of ABCA1 in Neuroscience 110,000 5% Alzheimer’s Disease Education and Research foundation 02/15/05- R21AG023662-02 “ABCA1: NIH/NIA $125,000 60% 01/31/07 A Potential Therapeutic Target for AD” 2003-2004 Role of ABCA1 and ApoA-I Pittsburgh Institute $25,000 10% in Amyloid-beta generation for Neurodegenerative disorders 2001-2002 Apolipoprotein A-I inhibition ADRC Pittsburgh $30,000 10% of A Aggregation and grant #AG05133 Neurotoxicity 6 6 Co-Investigator on Grants Years Grant and/or Contract Source Annual Direct Inclusive Number and Title Costs 2013-2016 “Role of APOE Isoforms in the Department of $166,000. 8% Pathogenesis of TBI induced defense Alzheimer's Disease” (PI I. Lefterov) 2012-2017 NIH/NIA $404,000 25% R01 Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD (PI I. Lefterov) Co-PI 2008-2010 R21 AG031956 Screening for NIH/NIA $175,000 10% LXR agonists-inhibitors of brain amyloidosis and inflammation (PI I. Lefterov) Co-PI 2008-2009 Identifying LXR activators for INSTITUTE FOR $150,000 10% Potential Treatment of THE STUDY OF Alzheimer's Disease AGING (PI: I. Lefterov) 2006-2008 R03AG028794 ABCA1 knock- NIH/NIA $50,000 5% in mouse model to study molecular pathology of AD (PI: I. Lefterov) Co-PI 2004-2006 R03AG023304 Therapeutic NIH/NIA $50,000 5% potential of LXR ligands in Alzheimer's Disease (PI: I. Lefterov) Co-PI Invited Lectureships and Major Seminars Related to Research-Past 5 years February 10, Regulation of APOE and its Invited Seminar Speaker, Department 2014 function in Alzheimer's disease of Neuroscience, Merck, West Point, by ABCA1 and nuclear PA receptors - a decade of research Nov, 2013 Apolipoprotein E, ABCA1 and Invited Seminar Speaker, Department A clearance. of Neuroscience, Genentech, South San Francisco, CA July, 2013 Apolipoprotein E and ABCA1: Annual Alzheimer’s Disease partners in A clearance meeting, Tel-Aviv University, Israel 7 7 June, 2013 Abca1 regulation of ApoE ApoE, ApoE Receptors & function: how significant is it for Neurodegeneration June 3-4th, 2013 - Alzheimer’s disease Georgetown University in Washington, DC October, 2012 Effect of Bexarotene on AD- Mini-symposium hosted by AHAF at phenotype of ApoE3 and ApoE4 the SfN 2012 annual meeting, New Orleans targeted replacement mice July, 2010 ABCA1 transporter and LXR: Sanders-Brown Center on Aging, emerging players and new targets Lexington, KY in AD September, Role of Abca1 transporter and LXR Department of Environmental and 2009 receptors in AD Occupational Health, University of Pittsburgh July 2008 LXR agonists for treatment of ICAD Meeting, Chicago, IL Alzheimer’s amyloidosis July, 2006 ABCA1 Transporter: A Nathan S. Kline Institute for Therapeutic Target for Alzheimer’s Psychiatric Research, Orangeburg, NY. disease June, 2006 LXR agonists for the treatment of “Obesity and Alzheimer’s Disease Alzheimer’s amyloidosis Workshop”, NIH/NIA Workshop, Washington, DC June, 2005 LXR and PPAR Synthetic Ligands International Conference on Prevention Upregulate ABCA1 Expression and of Dementia: Early diagnosis and Decrease A Secretion intervention, Washington, D.C. Other Research and Training Activities - NA 8 8 PUBLICATIONS Referred Articles Koldamova R, Fitz NF, Lefterov I. “ATP-Binding Cassette Transporter A1: From metabolism to Neurodegeneration” Neurobiol Dis. 2014 May 17. pii: S0969-
Load more

Recommended publications
  • Curcumin Effect on Bleomycin-Induced Pulmonary Fibrosis in Mus Musculus
    JITV Vol. 20 No 2 Th. 2015: 148-157 Curcumin Effect on Bleomycin-Induced Pulmonary Fibrosis in Mus musculus Rahmi A1, Setiyono A2, Juniantito V2 1Graduate School of Animal Biomedical Science, Faculty of Veterinary Medicine, Bogor Agricultural University 2Division of Pathology, Department of Clinic, Reproduction and Pathology, Faculty of Veterinary Medicine, Bogor Agricultural University E-mail: [email protected]; [email protected] (received 31-03-2015; revised 29-05-2015; accepted 04-06-2015) ABSTRAK Rahmi A, Setiyono A, Juniantito V. 2015. Pengaruh kurkumin terhadap fibrosis paru-paru akibat aplikasi bleomisin pada Mus musculus. JITV 20(2): 148-157. DOI: http://dx.doi.org/10.14334/jitv.v20i2.1169 Kurkumin merupakan bahan aktif utama dari tanaman kunyit (Curcuma longa) diketahui memiliki aktivitas sebagai anti- oksidan dan anti-inflamasi. Bleomisin merupakan salah satu obat anti-kanker yang dapat menginduksi fibrosis paru-paru pada manusia dan hewan. Tujuan penelitian ini adalah untuk mengetahui efek biologis kurkumin pada fibrosis paru-paru yang diinduksi bleomisin pada mencit. Sebanyak 16 ekor mencit galur ddy dibagi dalam 4 kelompok perlakuan: (i) kontrol, 100 µl aquadest steril diinjeksikan secara SC, (ii) bleomisin (BLM), 100 µl bleomisin konsentrasi 1 mg/ml diinjeksikan secara SC, (iii) kurkumin (CMN), 100 µl aquadest steril diinjeksikan secara SC dan 100 mg/kg BB kurkumin dalam 0,5% carboxymethylcellulose (CMC) yang diinjeksikan secara IP, dan (iv) BLM+CMN, 100 µl bleomisin dengan konsentrasi 1 mg/ml diinjeksikan secara SC dan 100 mg/kg BB kurkumin dalam 0,5% CMC diinjeksikan secara IP. Semua perlakuan diberikan setiap hari selama 4 minggu. Organ paru-paru dikoleksi dalam 10% buffered neutral formalin (BNF).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0010901 A1 Hibino Et Al
    US 20140010901A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0010901 A1 Hibino et al. (43) Pub. Date: Jan. 9, 2014 (54) BLEOMYCIN HYDROLASE PRODUCTION Publication Classification PROMOTOR (51) Int. Cl. A61E36/756 (2006.01) A63L/047 (2006.01) (75) Inventors: Toshihiko Hibino, Yokohama-shi (JP); A 6LX3/97 (2006.01) Shoko Yamada, Yokohama-shi (JP); A61E36/53 (2006.01) Hidekazu Fukushima, Yokohama-shi A61E36/23 (2006.01) (JP) (52) U.S. Cl. CPC ............... A61K 36/756 (2013.01); A61K 36/53 (2013.01); A61 K36/23 (2013.01); A61 K (73) Assignee: Shiseido Company, Ltd. 31/197 (2013.01); A61 K3I/047 (2013.01) USPC ........... 424/745; 424/769; 424/773; 424/777; (21) Appl. No.: 14/004,977 514/562; 514/738 (57) ABSTRACT (22) PCT Filed: Mar. 14, 2012 Provided is a novel bleomycin hydrolase production pro moter. (86). PCT No.: PCT/UP2012/056581 Provided is a bleomycin hydrolase production promoter, S371 (c)(1), natural moisturizing factor production promoter, and dry skin (2), (4) Date: Sep. 13, 2013 remedy, comprising as an active ingredient thereof one or a plurality of ingredients selected from the group consisting of (30) Foreign Application Priority Data chestnut rose extract, angelica root extract, cork tree bark extract, lamium album extract, rosemary extract, benzene Mar. 15, 2011 (JP) ................................. 2011-057126 sulfonyl GABA and erythritol. Patent Application Publication Jan. 9, 2014 Sheet 1 of 23 US 2014/0010901 A1 Fig.1 SPECIMEN 1 SPEC MEN 2 2 5 10 20 2 5 10 20 NUMBER OF TIMES OF TAPE STRIPPING Fig.2 SPECIMEN T N A M T, A: SUBJECTS NOT HAVING DRY SKIN N: SUBJECT HAVING SOMEWHAT DRY SKIN, MSUBJECT HAVING DRY SKN Patent Application Publication Jan.
    [Show full text]
  • In a Three-Dimensional Reconstructed Human Epidermis Filaggrin-2 Is Essential for Proper Cornification
    Citation: Cell Death and Disease (2015) 6, e1656; doi:10.1038/cddis.2015.29 OPEN & 2015 Macmillan Publishers Limited All rights reserved 2041-4889/15 www.nature.com/cddis In a three-dimensional reconstructed human epidermis filaggrin-2 is essential for proper cornification V Pendaries1,2,3, M Le Lamer1,2,3, L Cau1,2,3, B Hansmann4, J Malaisse5, S Kezic6, G Serre1,2,3 and M Simon*,1,2,3 Atopic dermatitis is a chronic inflammatory skin disease with defects in the epidermal barrier. In a cohort of African-American children, a FLG2 nonsense mutation has been associated with the disease. In the epidermis of European patients, the expression of filaggrin-2, the filaggrin-related protein encoded by FLG2, is decreased. To describe the function of filaggrin-2 and evaluate the impact of its deficiency, its expression was downregulated using lentivirus-mediated shRNA interference in a three-dimensional reconstructed human epidermis (RHE) model. This resulted in parakeratosis and a compact stratum corneum, presence of abnormal vesicles inside the corneocytes, increased pH and reduced amounts of free amino acids at the RHE surface, leading to increased sensitivity to UVB radiations. The expression of differentiation markers was slightly modified. However, we observed reduced proteolytic processing of corneodesmosin, hornerin and filaggrin in parallel with reduced amounts of caspase-14 and bleomycin hydrolase. Our data demonstrated that filaggrin-2 is important for a proper cornification and a functional stratum corneum. Its downregulation in atopic patients may be involved in the disease-associated epidermis impairment. Cell Death and Disease (2015) 6, e1656; doi:10.1038/cddis.2015.29; published online 19 February 2015 Atopic dermatitis (AD; OMIM #603165), also known as atopic homologous repeats and a S100-homologous N-terminal eczema, is a very common inflammatory skin disease.1,2 It is domain.
    [Show full text]
  • Biochemical Investigation of the Ubiquitin Carboxyl-Terminal Hydrolase Family" (2015)
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Spring 2015 Biochemical investigation of the ubiquitin carboxyl- terminal hydrolase family Joseph Rashon Chaney Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Biochemistry Commons, Biophysics Commons, and the Molecular Biology Commons Recommended Citation Chaney, Joseph Rashon, "Biochemical investigation of the ubiquitin carboxyl-terminal hydrolase family" (2015). Open Access Dissertations. 430. https://docs.lib.purdue.edu/open_access_dissertations/430 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. *UDGXDWH6FKRRO)RUP 8SGDWHG PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance 7KLVLVWRFHUWLI\WKDWWKHWKHVLVGLVVHUWDWLRQSUHSDUHG %\ Joseph Rashon Chaney (QWLWOHG BIOCHEMICAL INVESTIGATION OF THE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE FAMILY Doctor of Philosophy )RUWKHGHJUHHRI ,VDSSURYHGE\WKHILQDOH[DPLQLQJFRPPLWWHH Chittaranjan Das Angeline Lyon Christine A. Hrycyna George M. Bodner To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, Publication Delay, and Certification/Disclaimer (Graduate School Form 32), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Chittaranjan Das $SSURYHGE\0DMRU3URIHVVRU V BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB $SSURYHGE\R. E. Wild 04/24/2015 +HDGRIWKH'HSDUWPHQW*UDGXDWH3URJUDP 'DWH BIOCHEMICAL INVESTIGATION OF THE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE FAMILY Dissertation Submitted to the Faculty of Purdue University by Joseph Rashon Chaney In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 2015 Purdue University West Lafayette, Indiana ii All of this I dedicate wife, Millicent, to my faithful and beautiful children, Josh and Caleb.
    [Show full text]
  • Families and Clans of Cysteine Peptidases
    Families and clans of eysteine peptidases Alan J. Barrett* and Neil D. Rawlings Peptidase Laboratory. Department of Immunology, The Babraham Institute, Cambridge CB2 4AT,, UK. Summary The known cysteine peptidases have been classified into 35 sequence families. We argue that these have arisen from at least five separate evolutionary origins, each of which is represented by a set of one or more modern-day families, termed a clan. Clan CA is the largest, containing the papain family, C1, and others with the Cys/His catalytic dyad. Clan CB (His/Cys dyad) contains enzymes from RNA viruses that are distantly related to chymotrypsin. The peptidases of clan CC are also from RNA viruses, but have papain-like Cys/His catalytic sites. Clans CD and CE contain only one family each, those of interleukin-ll3-converting enz3wne and adenovirus L3 proteinase, respectively. A few families cannot yet be assigned to clans. In view of the number of separate origins of enzymes of this type, one should be cautious in generalising about the catalytic mechanisms and other properties of cysteine peptidases as a whole. In contrast, it may be safer to gener- alise for enzymes within a single family or clan. Introduction Peptidases in which the thiol group of a cysteine residue serves as the nucleophile in catalysis are defined as cysteine peptidases. In all the cysteine peptidases discovered so far, the activity depends upon a catalytic dyad, the second member of which is a histidine residue acting as a general base. The majority of cysteine peptidases are endopeptidases, but some act additionally or exclusively as exopeptidases.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • Knockdown of Filaggrin in a Three-Dimensional Reconstructed
    ORIGINAL ARTICLE Knockdown of Filaggrin in a Three-Dimensional Reconstructed Human Epidermis Impairs Keratinocyte Differentiation Vale´rie Pendaries1,2,3, Jeremy Malaisse4, Laurence Pellerin1,2,3, Marina Le Lamer1,2,3, Rachida Nachat1,2,3,8, Sanja Kezic5, Anne-Marie Schmitt6,CarlePaul1,2,3,7, Yves Poumay4, Guy Serre1,2,3 and Michel Simon1,2,3 Atopic dermatitis is a chronic inflammatory skin disorder characterized by defects in the epidermal barrier and keratinocyte differentiation. The expression of filaggrin, a protein thought to have a major role in the function of the epidermis, is downregulated. However, the impact of this deficiency on keratinocytes is not really known. This was investigated using lentivirus-mediated small-hairpin RNA interference in a three-dimensional recon- structed human epidermis (RHE) model, in the absence of other cell types than keratinocytes. Similar to what is known for atopic skin, the experimental filaggrin downregulation resulted in hypogranulosis, a disturbed corneocyte intracellular matrix, reduced amounts of natural moisturizing factor components, increased permeability and UV-B sensitivity of the RHE, and impaired keratinocyte differentiation at the messenger RNA and protein levels. In particular, the amounts of two filaggrin-related proteins and one protease involved in the degradation of filaggrin, bleomycin hydrolase, were lower. In addition, caspase-14 activation was reduced. These results demonstrate the importance of filaggrin for the stratum corneum properties/functions. They indicate that filaggrin downregulation in the epidermis of atopic patients, either acquired or innate, may be directly responsible for some of the disease-related alterations in the epidermal differentiation program and epidermal barrier function. Journal of Investigative Dermatology advance online publication, 10 July 2014; doi:10.1038/jid.2014.259 INTRODUCTION a secondary local epidermal barrier disruption.
    [Show full text]
  • Genomic Structure and Genetic Mapping of the Human Neutral Cysteine Protease Bleomycin Hydrolase'
    (CANCER RESEARCH57. 4191—4195,October1, 1997] Advances in Brief Genomic Structure and Genetic Mapping of the Human Neutral Cysteine Protease Bleomycin Hydrolase' Susana E. Montoya, Robert E. Ferrell, and John S. Lazo2 Departments ofHuman Genetics [S. E. M., R. E. F.J and Pharmacology [J. S. LI, University of Pittsburgh, Pittsburgh. Pennsylvania 1526/ Abstract reported to bind DNA and to act as a repressor of the Gal4 regulatory system (10). Thus, BH, which has been conserved during evolution, is Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that likely to have important physiological functions in human cells in inactivates the widely used antineoplastic agent bleomycin (BLM) and is a cluding its key role in drug metabolism. We now report the genetic primary candidate gene for protection against lethal BLM-induced pul monary fibrosis and for BLM resistance in tumors. Human B!! was found mapping of the human BH gene and its overall genomic organization, to exist as a single gene that was mapped to chromosome 17 using National which corroborates membership in the cysteine protease superfamily. Institute of General Medical Sciences human/rodent hybrid mapping panels and localized to 17q11.1—11.2 by linkage analysis using the Centre Materials and Methods d'Etude du Polymorphisme Humain reference database. The human BH gene consisted of 11 exons ranging in size from 69—198bpseparated by Characterization of Human BH Genomic Structure. Amplification introns ofapproximately 1kb, reflectingthe archetypal genomicstructure primers (Fig. 1) from adjacent exons were designed using the human cDNA of the cysteine protease family. A polymorphic site was identified in the sequence (8) and intron-exon boundary data from the 5' end of the mouse BH eleventh exon at bp 1450 encodIng either valine or Isoleucine.
    [Show full text]
  • Cold Adaptation in Antarctic Notothenioids
    International Journal of Molecular Sciences Article Cold Adaptation in Antarctic Notothenioids: Comparative Transcriptomics Reveals Novel Insights in the Peculiar Role of Gills and Highlights Signatures of Cobalamin Deficiency Federico Ansaloni 1,2 , Marco Gerdol 1,* , Valentina Torboli 1, Nicola Reinaldo Fornaini 1,3, Samuele Greco 1 , Piero Giulio Giulianini 1 , Maria Rosaria Coscia 4, Andrea Miccoli 5 , Gianfranco Santovito 6 , Francesco Buonocore 5 , Giuseppe Scapigliati 5,† and Alberto Pallavicini 1,7,8,† 1 Department of Life Sciences, University of Trieste, 34127 Trieste, Italy; [email protected] (F.A.); [email protected] (V.T.); [email protected] (N.R.F.); [email protected] (S.G.); [email protected] (P.G.G.); [email protected] (A.P.) 2 International School for Advanced Studies, 34136 Trieste, Italy 3 Department of Cell Biology, Charles University, 12800 Prague, Czech Republic 4 Institute of Biochemistry and Cell Biology, National Research Council of Italy, 80131 Naples, Italy; [email protected] 5 Department for Innovation in Biological, Agro-Food and Forest Systems, University of Tuscia, 01100 Viterbo, Italy; [email protected] (A.M.); [email protected] (F.B.); [email protected] (G.S.) 6 Department of Biology, University of Padua, 35131 Padua, Italy; [email protected] 7 Anton Dohrn Zoological Station, 80122 Naples, Italy 8 National Institute of Oceanography and Experimental Geophysics, 34010 Trieste, Italy * Correspondence: [email protected] Citation: Ansaloni, F.; Gerdol, M.; † These authors contributed equally to this work. Torboli, V.; Fornaini, N.R.; Greco, S.; Giulianini, P.G.; Coscia, M.R.; Miccoli, A.; Santovito, G.; Buonocore, F.; et al.
    [Show full text]
  • Oncogenic Parallels in Alzheimer Disease
    ONCOGENIC PARALLELS IN ALZHEIMER DISEASE by ARUN K. RAINA Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisors Dr. Mark A. Smith & Dr. Xiongwei Zhu Department of Pathology Case Western Reserve University Janurary 2005 Copyright © 2005 by Arun K. Raina All rights reserved ii CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ARUN K. RAINA candidate for the Ph.D. degree *. (signed)___George Perry___________________________ (chair of the committee) ____Mark A. Smith__________________________ ____Xiongwei Zhu___________________________ ____Robert B. Petersen__________________________ ____David Boothman__________________________ (date) ____________________ *We also certify that written approval has been obtained for any proprietary material contained therein. iii Dedication To Bhairavah Uma, Autar, Arvind and P iv Table of Contents List of Tables 7 List of Figures 8 Acknowledgements 11 Abbreviations 12 Abstract 16 Chapter 1 Introduction 18 1.1 Historical 18 1.2 Definition of Dementias 19 1.3 Epidemiology of AD 19 1.4 Pathology of AD 19 a. Neurofibrillary Tangles 20 b. Senile Plaques 22 1.5 Clinical Features of AD 22 1.6 Etiopathogenesis of AD 23 a. Age 23 b. Genetics 24 i. Amyloid β Protien Precursor (AβPP) 24 ii. Presenilins 1 and 2 25 iii. ApoE 25 c. Oxidative Stress 27 d. Cell Cycle and AD 28 1 Chapter 2 Oxidative Stress in AD 30 2.1 Introduction 30 a. Oxidative Stress in AD 30 b. Oxidative Events and Apoptosis in AD 32 c. Oxidative and Cell Cycle Events in AD 33 d. Oxidative Stress - An Adaptation in AD? 34 e. Oxidative Relevance to Lesions 35 f.
    [Show full text]
  • Wo 2008/127646 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127646 A2 (51) International Patent Classification: Not classified AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (21) International Application Number: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, PCT/US2008/004699 IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, (22) International Filing Date: 10 April 2008 (10.04.2008) MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, (25) Filing Language: English PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 60/922,994 11 April 2007 (11.04.2007) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): BIOVER- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), DANT, INC. [US/US] ; 7330 Carroll Road, San Diego, CA European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, 92121 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Caspase-14 Is Required for Filaggrin Degradation to Natural Moisturizing
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector See related commentary on pg 2173 ORIGINAL ARTICLE Caspase-14 Is Required for Filaggrin Degradation to Natural Moisturizing Factors in the Skin Esther Hoste1,2,11, Patrick Kemperman3,4,11, Michael Devos1,2,11, Geertrui Denecker1,2, Sanja Kezic5, Nico Yau5, Barbara Gilbert1,2, Saskia Lippens1,2, Philippe De Groote1,2, Ria Roelandt1,2, Petra Van Damme6, Kris Gevaert6, Richard B. Presland7,8, Hidenari Takahara9, Gerwin Puppels3,10, Peter Caspers3,10, Peter Vandenabeele1,2 and Wim Declercq1,2 Caspase-14 is a protease that is mainly expressed in suprabasal epidermal layers and activated during keratinocyte cornification. Caspase-14-deficient mice display reduced epidermal barrier function and increased sensitivity to UVB radiation. In these mice, profilaggrin, a protein with a pivotal role in skin barrier function, is processed correctly to its functional filaggrin (FLG) repeat unit, but proteolytic FLG fragments accumulate in the epidermis. In wild-type stratum corneum, FLG is degraded into free amino acids, some of which contribute to generation of the natural moisturizing factors (NMFs) that maintain epidermal hydration. We found that caspase-14 cleaves the FLG repeat unit and identified two caspase-14 cleavage sites. These results indicate that accumulation of FLG fragments in caspase-14À/À mice is due to a defect in the terminal FLG degradation pathway. Consequently, we show that the defective FLG degradation in caspase-14-deficient skin results in substantial reduction in the amount of NMFs, such as urocanic acid and pyrrolidone carboxylic acid.
    [Show full text]